


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-65. (Cancelled)

66. (Amended) A method for identifying a chemosensitizing compound selected from compounds of Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R<sup>1</sup> is hydrogen or alkoxy of 1 to 10 carbon atoms;

R<sup>2</sup> is hydrogen or alkenyl of 2 to 10 carbon atoms;

R<sup>3</sup> is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R<sup>7</sup>NH(CH<sub>2</sub>)<sub>v</sub>— or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are hydrogen;

R<sup>7</sup> is H or



R<sup>8</sup> is selected from alkyl of 1 to 10 carbon atoms, —(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>H,



or a pharmaceutically acceptable salt thereof, Fumitremorgin A, Fumitremorgin B and Fumitremorgin C that reverses BCRP-mediated multiple drug resistance in cancer cells which exhibit BCRP-mediated multiple drug resistance which comprises:

- a. contacting said S1-M1-3.2 cancer cells with a test compound selected from compounds of Formula I, Fumitremorgin A, Fumitremorgin B or Fumitremorgin C and a chemotherapeutic agent to which said cancer cells are resistant and measuring cancer cell survival;
- b. contacting said cancer cells with a chemotherapeutic agent to which said cancer cells are resistant and measuring cancer cell survival;
- c. comparing cancer cell survival of step a to step b; and
- d. identifying a test compound selected from compounds of Formula I, Fumitremorgin A, Fumitremorgin B and Fumitremorgin C ~~compound which shows an increase in cancer cell death in step a as compared to step b, which indicates that said test chemosensitizing compound is a chemosensitizing compound, wherein an increase in cancer cell death in step a as compared to step b is about 22% or above.~~

67. (Previously presented) A method according to claim 66 wherein the chemotherapeutic agent is selected from mitoxantrone, doxorubicin, and topotecan.

68-69. (Cancelled)